Noah S. Kornblum, MD, assistant professor of medicine, Albert Einstein College of Medicine, attending physician of medicine, Montefiore-Einstein Center for Cancer Care, discusses the results from the PrECOG 0102 study, which explored the addition of everolimus (Afinitor) to fulvestrant (Faslodex) as a treatment for patients with metastatic hormone receptor (HR)—positive, HER2-negative breast cancer.

The primary endpoint of the PrECOG 0102 study was progression-free survival (PFS). It was found that the combination of everolimus and fulvestrant doubled PFS from 5.1 months to 10.4 months. This has been consistent with the type of response seen in the BOLERO-2 trial looking at everolimus in combination with exemestane.

Fulvestrant alone had a PFS of 5.1 months, suggesting that in the aromatase inhibitor-resistant population, fulvestrant might be more beneficial to combine with everolimus, explains Kornblum.

Videos

Noah S. Kornblum, MD, assistant professor of medicine, Albert Einstein College of Medicine, attending physician of medicine, Montefiore-Einstein Center for Cancer Care, discusses the results from the PrECOG 0102 study, which explored the addition of everolimus (Afinitor) to fulvestrant (Faslodex) as a treatment for patients with metastatic hormone receptor (HR)–positive, HER2-negative breast cancer.

Dr. Kornblum on Results of PrECOG 0102 in Breast Cancer

Noah S. Kornblum, MD, assistant professor of medicine, Albert Einstein College of Medicine, and attending physician of medicine, Montefiore-Einstein Center for Cancer Care, discusses the phase II PrECOG 0102 trial, which explored the addition of everolimus (Afinitor) to fulvestrant (Faslodex) as a treatment for patients with metastatic hormone receptor (HR)—positive, HER2-negative breast cancer.

PrECOG 0102 was a randomized, double-blind, phase II study. Here, the everolimus/fulvestrant combination doubled median progression-free survival rates compared with fulvestrant alone, from 5.1 months on fulvestrant to 10.4 months with the combination (HR, 0.60; 95% CI, 0.40-0.92; 

The PI3k/Akt/mTOR pathway is usually a variant in aromatase inhibitor or endocrine resistant breast cancer in multiple ways, Kornblum explains. The logic behind the investigative regimen was to target the mTOR pathway with a mTOR inhibitor in combination with an established endocrine backbone, such as fulvestrant. Fulvestrant was chosen as it has more potent estrogen receptor-inhibitory activity than an agent such as exemestane.

View more from the 2016 San Antonio Breast Cancer Symposium

Noah S. Kornblum, MD, assistant professor of medicine, Albert Einstein College of Medicine, and attending physician of medicine, Montefiore-Einstein Center for Cancer Care, discusses the phase II PrECOG 0102 trial, which explored the addition of everolimus (Afinitor) to fulvestrant (Faslodex) as a treatment for patients with metastatic hormone receptor (HR)–positive, HER2-negative breast cancer.

Noah S. Kornblum, MD

Articles

Dr. Kornblum on Results of PrECOG 0102 in Breast Cancer

Dr. Kornblum on Impact of PrECOG 0102 Trial for HR+/HER2- Breast Cancer